# AUGMENT-101 (NCT04065399)

> A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04065399
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Syndax Pharmaceuticals
- Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Mixed Lineage Acute Leukemia; Mixed Phenotype Acute Leukemia; Acute Leukemia of Ambiguous Lineage
- Interventions: revumenib; cobicistat
- Enrollment: 447
- Primary outcome: Number of participants with dose-limiting toxicities (DLTs) (Phase 1)
- Primary outcome: Number of participants with treatment-emergent adverse events (TEAEs) (Phase 1)
- Primary outcome: Cmax (Phase 1)
- Primary outcome: Tmax (Phase 1)
- Primary outcome: AUC0-t (Phase 1)
- Primary outcome: CR+CRh rate (Phase 2 [Cohorts 2A-2C])
- Primary outcome: Number of participants with TEAEs (Phase 2 [Cohorts 2A-2C])
- Primary outcome: Cmax (Phase 2 [Cohort 2D])
- Primary outcome: AUC0-tau (Phase 2 [Cohort 2D])

## Commentary we found

- YouTube: 37
- Podcasts: 30
- X threads: 26
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=augment-101-nct04065399

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04065399", "email": "<work email>"}; the inbox owner confirms by the emailed link.